<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01527552</url>
  </required_header>
  <id_info>
    <org_study_id>BIASP-1488</org_study_id>
    <nct_id>NCT01527552</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects</brief_title>
  <official_title>A Single-Centre, Randomised, Balanced, Double-Blind, Cross-Over Trial Investigating the Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Africa. The aim of this trial is to investigate the bioequivalence
      of two formulations of biphasic insulin aspart 50 in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2002</start_date>
  <completion_date type="Actual">December 18, 2002</completion_date>
  <primary_completion_date type="Actual">December 18, 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the insulin aspart curve in the interval from 0-16 hours</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax, maximum insulin aspart concentration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax, the time to maximum insulin aspart concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the insulin aspart curve</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the glucose infusion rate curve</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIRmax, maximum glucose infusion rate value</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tGIRmax, time to maximum glucose infusion rate value</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 50</intervention_name>
    <description>A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days</description>
    <arm_group_label>Formulation A</arm_group_label>
    <arm_group_label>Formulation B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Considered generally healthy upon completion of medical history and physical
             examination, as judged by the investigator

          -  Body Mass Index (BMI) between 19-29 kg/m^2 (both inclusive)

          -  Minimum body weight of 65 kg

          -  Fasting blood glucose between 3.8-6.0 mmol/L

          -  Glycohemoglobin (HbA1c) below 6.4 %

          -  Non-smokers

        Exclusion Criteria:

          -  Clinically significant abnormal hematology, biochemistry, urinalysis or ECG
             (electrocardiogram) screening tests, as judged by the investigator

          -  A history of any illness that, in the opinion of the Investigator and/or Sponsor,
             might confound the results of the study or pose additional risk in administering the
             investigational product to the subject

          -  History of or current addiction to alcohol or drugs of abuse as determined by the
             investigator (positive drug/alcohol abuse screen)

          -  Hepatitis B or C

          -  Subjects with a first-degree relative with diabetes mellitus

          -  Known or suspected allergy to trial product or related products

          -  Smoking during the past three months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9324</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

